drugset / Trial / NCT05363917
Natrunix Versus Methotrexate in Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix versus MTX (+folate) for the Treatment of Rheumatoid Arthritis
Timeline
- Start
- 2022-06-15
- Primary completion
- 2022-12-15
- Completion
- 2023-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 7.5 mg | Oral |
| Comparator | Methotrexate | Small molecule | 15 mg | Oral |
| Subject | Natrunix | Monoclonal antibody | 400 mg | Subcutaneous |
| Background | Leucovorin | Small molecule | 5 mg | Oral |
| Background | folic acid | Other / unclassified | 1 mg | Oral |